beta(2)-adrenoceptors activate nitric oxide synthase in human platelets

L R Queen; B Xu; K Horinouchi; I Fisher; A Ferro

beta(2)-adrenoceptors activate nitric oxide synthase in human platelets

L R Queen, B Xu, K Horinouchi, I Fisher, A Ferro

Research output: Contribution to journal › Article › peer-review

Abstract

Nitric oxide (NO), generated by platelets through stimulation of nitric oxide synthase (NOS), limits platelet adhesion and aggregation after a prothrombotic stimulus. Platelet beta-adrenoceptors (beta ARs) mediate inhibition of aggregation, but no direct link has been shown between these receptors and platelet adhesion or NO production. We examined NOS activity in human platelets from the conversion of L-[H-3]-arginine to L-[H-3]-citrulline, after beta AR stimulation or cAMP elevation. Basal NOS activity was 0.11+/-0.03 pmol L-citrulline/10(8) platelets. The beta AR agonist isoproterenol 1 mu mol/L and the adenylyl cyclase activator forskolin 1 mu mol/L each increased NOS activity, to 0.26+/-0.04 and 0.23+/-0.03 pmol L-citrulline/10(8) platelets, respectively (P

Original language	English
Pages (from-to)	39 - 44
Number of pages	6
Journal	Circulation Research
Volume	87
Issue number	1
Publication status	Published - 2000

Cite this

@article{ad36d471394344c19cc84dcd337c99b3,

title = "beta(2)-adrenoceptors activate nitric oxide synthase in human platelets",

abstract = "Nitric oxide (NO), generated by platelets through stimulation of nitric oxide synthase (NOS), limits platelet adhesion and aggregation after a prothrombotic stimulus. Platelet beta-adrenoceptors (beta ARs) mediate inhibition of aggregation, but no direct link has been shown between these receptors and platelet adhesion or NO production. We examined NOS activity in human platelets from the conversion of L-[H-3]-arginine to L-[H-3]-citrulline, after beta AR stimulation or cAMP elevation. Basal NOS activity was 0.11+/-0.03 pmol L-citrulline/10(8) platelets. The beta AR agonist isoproterenol 1 mu mol/L and the adenylyl cyclase activator forskolin 1 mu mol/L each increased NOS activity, to 0.26+/-0.04 and 0.23+/-0.03 pmol L-citrulline/10(8) platelets, respectively (P",

author = "Queen, {L R} and B Xu and K Horinouchi and I Fisher and A Ferro",

year = "2000",

language = "English",

volume = "87",

pages = "39 -- 44",

journal = "Circulation Research",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - beta(2)-adrenoceptors activate nitric oxide synthase in human platelets

AU - Queen, L R

AU - Xu, B

AU - Horinouchi, K

AU - Fisher, I

AU - Ferro, A

PY - 2000

Y1 - 2000

N2 - Nitric oxide (NO), generated by platelets through stimulation of nitric oxide synthase (NOS), limits platelet adhesion and aggregation after a prothrombotic stimulus. Platelet beta-adrenoceptors (beta ARs) mediate inhibition of aggregation, but no direct link has been shown between these receptors and platelet adhesion or NO production. We examined NOS activity in human platelets from the conversion of L-[H-3]-arginine to L-[H-3]-citrulline, after beta AR stimulation or cAMP elevation. Basal NOS activity was 0.11+/-0.03 pmol L-citrulline/10(8) platelets. The beta AR agonist isoproterenol 1 mu mol/L and the adenylyl cyclase activator forskolin 1 mu mol/L each increased NOS activity, to 0.26+/-0.04 and 0.23+/-0.03 pmol L-citrulline/10(8) platelets, respectively (P

AB - Nitric oxide (NO), generated by platelets through stimulation of nitric oxide synthase (NOS), limits platelet adhesion and aggregation after a prothrombotic stimulus. Platelet beta-adrenoceptors (beta ARs) mediate inhibition of aggregation, but no direct link has been shown between these receptors and platelet adhesion or NO production. We examined NOS activity in human platelets from the conversion of L-[H-3]-arginine to L-[H-3]-citrulline, after beta AR stimulation or cAMP elevation. Basal NOS activity was 0.11+/-0.03 pmol L-citrulline/10(8) platelets. The beta AR agonist isoproterenol 1 mu mol/L and the adenylyl cyclase activator forskolin 1 mu mol/L each increased NOS activity, to 0.26+/-0.04 and 0.23+/-0.03 pmol L-citrulline/10(8) platelets, respectively (P

M3 - Article

VL - 87

SP - 39

EP - 44

JO - Circulation Research

JF - Circulation Research

IS - 1

ER -